# Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-230d5ab3
Ticker: NTLA
Company: Intellia
Source: Intellia
Published: 2026-07-06 20:05 EST
Original Source URL: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-inducement-grants-under-nasdaq-20
## Summary

The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.

## Article Body
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 53,250 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx .

Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. jason.fredette@intelliatx.com

Media Contact: Mike Tattory Vice President LifeSci Communications mtattory@lifescicomms.com
## Recent Company News
- 2026-07-06 20:05 EST — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-230d5ab3) — Source: Intellia
- 2026-06-13 11:30 EST — [Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-for-lonvoguran-d89fa3fd) — Source: Intellia
- 2026-06-05 20:05 EST — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-aa05e073) — Source: Intellia
- 2026-06-01 11:30 EST — [Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-to-report-additional-phase-3-haelo-data-for-lonvoguran-ziclumeran-lonvo-z-in-late-breaking-oral-presentation-at-eaaci-2026) — Source: Intellia
- 2026-05-11 11:30 EST — [Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates) — Source: Intellia
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)